Amicus Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
We have Amicus Therapeutics here with us today. With us from Amicus is John Crowley, Chairman and CEO. Thank you so much for joining us at the UBS Healthcare Conference.
Questions & Answers
And maybe just to kick it off, John, just for some background, those who are newer to the story. Can you give us a quick overview of Amicus' rare disease portfolio and, I guess, key goals for the company in the coming years?
Great. Of course, Ellie. Thank you, and thank you for having me. I apologize I have to join by telephone here. I guess I didn't have the latest version of Google Chrome updated. But thank you, everybody, for listening.
To remind everybody, Amicus is a global biotechnology company, and we focus in the rare diseases, and we have since the founding of the company. We have a range of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |